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Edited by Lukas HuberAbstract POEM, also called nephronectin, is an extracellular
matrix protein that is considered to play a critical role as an
adhesion molecule in the development and functioning of various
tissues, such as kidneys and bones. In the present study, we
examined the molecular mechanism of POEM gene expression,
and found that transforming growth factor-b (TGF-b) strongly
inhibited POEM expression in the mouse osteoblastic cell line,
MC3T3-E1. TGF-b-induced decrease of POEM expression oc-
curred in both time- and dose-dependent manners through the
activation of TGF-b receptor I and extracellular signal-regulated
kinase/c-Jun N-terminal kinase pathways.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Previously, we identiﬁed a novel EGF-like repeat protein,
POEM (pre-osteoblast epidermal growth factor-like repeat
protein with meprin, A5 protein, and receptor protein–tyrosine
phosphatase l domain), also known as nephronectin. This
protein is an adhesion molecule with ﬁve EGF-like domains,
an Arg-Gly-Asp (RGD) cell binding motif, and meprin, A5
protein, and receptor protein–tyrosine phosphatase l (MAM)
domain [1,2]. It belongs to a group of small type EGF-repeat
proteins such as MAEG, Pref-1, Del1, DANCE, S1-5, DBI,
and Spe-9, all of which play important roles in the diﬀerentia-
tion and development of various organs [3–8]. POEM is associ-
ated with integrins, especially a8b1, which is an extracellular
matrix receptor, through its own RGD motif and possesses
strong cell adhesion, spreading, and survival-promoting activi-
ties [1,2].
In mouse embryos, POEM mRNA has a unique distribution
in and around developing bone, as well as in tooth germ and
muscle tissues [1], suggesting a relationship between POEMAbbreviations: ALK, activin-like receptor kinase; ERK, extracellular
signal-regulated kinase; JNK, c-Jun N-terminal kinase; MEK, MAPK-
ERK kinase
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doi:10.1016/j.febslet.2007.10.021and bone metabolism. In a recent study of the physiological
functions of POEM using mice lacking nephronectin/POEM,
Linton et al. found that POEM is essential for kidney develop-
ment via glial cell line-derived neurotrophic factor (GDNF)
production [9]. However, there are no reports regarding skele-
tal defects in nephronectin/POEM-deﬁcient mice, and the pre-
cise physiological and functional roles of POEM in bone
metabolism are not yet understood. To examine the molecular
mechanism of POEM gene expression in osteoblasts, we
focused on the eﬀect of transforming growth factor-b (TGF-
b) which was identiﬁed by screening for POEM gene regula-
tory reagents.
TGF-b, a secreted factor present at high levels in bone,
inhibits the progression of osteoblast diﬀerentiation in culture.
It plays a key role in osteoblast diﬀerentiation and bone devel-
opment and remodeling. Osteoblasts secrete and deposit TGF-
b into the bone matrix and can respond to it, thus enabling
possible autocrine modes of action [10]. TGF-b regulates the
proliferation and diﬀerentiation of osteoblasts both in vitro
and in vivo. The eﬀects of TGF-b on osteoblast diﬀerentiation
depend on the extracellular environment and the diﬀerentia-
tion stage of cells. TGF-b stimulates proliferation and early
osteoblast diﬀerentiation, while inhibiting terminal diﬀerentia-
tion [11,12].
TGF-b signaling is initiated by ligand binding to a heterotet-
rameric cell–surface receptor complex comprising two types of
transmembrane serine/threonine kinases. Ligand-induced
phosphorylation of type I [TGF-b R1, activin-like receptor
kinase (ALK)5] by type II receptors results in the activation
of type I receptor kinases, which in turn phosphorylate and
activate receptor-activated SMADs (R-SMADs). These
R-SAMDs then form a complex with a common SMAD4.
Activated SMAD complexes translocate into the nucleus,
where they regulate transcription of target genes [13,14].
Besides SMAD-mediated transcription, TGF-b activates other
signaling cascades including MAPK [extracellular signal-regu-
lated kinase (ERK)1 and ERK2 (ERK1/2), p38 MAPK, and
c-Jun N-terminal kinase (JNK)] pathways. TGF-b-induced
activation of the ERK1/2 and JNK pathways can result in
SMAD phosphorylation and regulate SMAD activation [15].
The present study investigated the mechanisms governing
the regulation of POEM expression by TGF-b. We demon-
strated that TGF-b is implicated in the negative regulation
of POEM gene expression in a time- and dose-dependent man-
ner through TGF-b R1 and MAPK pathways in osteoblasts.blished by Elsevier B.V. All rights reserved.
su
lin
on
tro
l
PS -4 G
F-
β
G
E2
5322 A. Miyazono et al. / FEBS Letters 581 (2007) 5321–53262. Materials and methods
2.1. Reagent
Human TGF-b 1 and mouse IL-4 were purchased from R&D system
(Minneapolis, MN, USA). Mouse EGF was purchased from Pepro-
Tech Inc. (Rocky Hill, NJ, USA). Human BMP-2 was obtained from
Astellas Pharmaceuticals Co. Ltd. (Tokyo, Japan). TGF-b receptor I
kinase inhibitor II (2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-
naphthyridine), PD98059 and SB203580 were purchased from EMD
Chemicals Inc. (San Diego, CA, USA). Lipopolysaccharide (LPS),
Insulin, prostaglandin E2 (PGE2) and SP600125 were purchased from
SIGMA (St. Louis, MO, USA).InC L IL T
POEM
GAPDH
P
Fig. 1. Inhibition of POEMmRNA expression by TGF-b. MC3T3-E1
cells were treated with selected reagents (10 ng/ml of LPS and IL-4,
1 ng/ml of TGF-b, 10 nM of Insulin and PGE2) for 24 h. Total cellular
RNAs were extracted and mRNA for POEM and GAPDH were
examined by Northern blot analysis.
A
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POEM2.2. Cell culture
Primary calvarial osteoblasts were obtained from the calvariae of
neonatal ddY mice (Saitama Experimental Animals, Saitama, Japan)
using 0.1% collagenase and 0.2% dispase [16]. Primary osteoblasts
and MC3T3-E1 cells (RIKEN BioResource Center, Ibaraki, Japan)
were cultured in MEMa (Wako Pure Chemical Industries Ltd., Osaka,
Japan) supplemented with 10% Fetal Bovine Serum and penicillin–
streptomycin (Invitrogen, Carlsbad, CA, USA) at 37 C in a CO2 incu-
bator (5% CO2, 95% air).
2.3. Northern blot analysis
Ten micrograms of total RNAs was electrophoresed on a 1% aga-
rose gel containing 2% formaldehyde and transferred to a nylon mem-
brane (Hybond N, GE Healthcare UK Ltd., Buckinghamshire, UK).
Northern hybridization of the ﬁlters with POEM and GAPDH probes
were performed in Perfect Hybridization solution (SIGMA) overnight
at 65 C. The membranes were washed twice with 2 · SSC containing
0.5% SDS at 65 C for 30 min, once with 2 · SSC at 65 C for 30 min,
followed by exposure to a storm phosphoimager screen (Molecular
Dynamics, Sunnyvale, CA, USA).B
C
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Culture Period (h)2.4. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total cellular RNAs extracted with TRIzol reagent (Invitrogen) were
reverse-transcribed using SuperScript III (Invitrogen) according to the
manufacturer’s protocols. Polymerase chain reaction (PCR) was per-
formed using TaqDNA polymerase (SIGMA) under the following con-
ditions: denaturation at 94 C for 5 min, followed by 30 repeated cycles
at 94 C for 30 s, annealing at 55 C for 45 s, and extension at 72 C for
30 s. Alkaline phosphatase (ALP), 5 0-GATCATTCCCACGTTTT-
CAC-3 0 and 5 0-TGCGGGCTTGTGGGACCTGC-3 0; osteocalcin, 5 0-
CAAGTCCCACACAGCAGCTT-30 and 5 0-AAAGCCGAGCTGC-
CAGAGTT-3 0; BSP, 5 0-ATGGCCTGTGCTTTCTCGAT-3 0 and 5 0-
AAACCCGTTCAGAAGGACAG-30; TGF-b receptor I, 5 0-CGCAA-
GACTCACAGCTCTAC-3 0 and 5 0-AGAGCCACTGTCTTAATGC-
C-3 0; TGF-b receptor II, 5 0-AGGCCAAGCTGAAGCAGAAC-30
and 5 0-CCGAAGTCACACAGGCAACA-3 0; GAPDH, 5 0-GAAGG-
TCGGTGTGAACGGATTTGGC-30 and 5 0-CATGTAGGCCATG-
AGGTCCACCAC-3 0.(1 ng/ml)
ALP
osteocalcin
BSP
GAPDH
Fig. 2. Dose- and time-dependent inhibition of POEM mRNA
expression by TGF-b. (A and B) Dose eﬀects of TGF-b on POEM2.5. Western blot analysis
Cell lysates were separated by 10% SDS–PAGE and transferred
onto PVDF membrane (Milipore, Billerica, MA). The blots were
probed with the ﬁrst antibodies described below followed by incuba-
tion with horseradish peroxidase-conjugated anti-rabbit IgG. Antibod-
ies against ERK1/2, p38 MAPK, JNK, and phospho-ERK1/2, p38
MAPK, JNK were purchased from Cell Signaling Technology Inc.
(Boston, MA, USA). The protein was visualized using enhanced
chemiluminescence reagent (ECL-plus, GE Healthcare UK Ltd.,
Buckinghamshire, UK).mRNA expression. MC3T3-E1 cells were treated with 0.1, 1, 10, 100,
or 1000 pg/ml TGF-b for 48 h. Time course analysis of TGF-b eﬀects
on POEM mRNA expression. MC3T3-E1 cells were treated with 1 ng/
ml TGF-b for 3, 6, 12, 24, or 48 h. Total cellular RNAs were extracted
and mRNA for POEM and GAPDH were examined by Northern blot
analysis. (C) Time course analysis of TGF-b eﬀects on ALP,
osteocalcin, and BSP. MC3T3-E1 cells were treated with 1 ng/ml
TGF-b for 12, 24, or 48 h. Total cellular RNAs were extracted and
mRNA for ALP, osteocalcin, and BSP were examined by RT-PCR.
The size of PCR products were 470 bp for ALP, 862 bp for osteocalcin,
690 bp for BSP and 982 bp for GAPDH.3. Results
3.1. TGF-b suppressed expression of POEM mRNA
To study the eﬀect of several reagents that regulate osteo-
blast functions, on the levels of POEM mRNA expression,
MC3T3-E1 cells were used. These cells, established from new-
born mouse calvaria and selected on the basis of high ALPactivity in the conﬂuent state, constitutively express modest
levels of POEM mRNA [1,17]. When treated with LPS, IL-4,
TGF-b, Insulin and PGE2 for 24 h, TGF-b, but not other re-
agents, strongly inhibited the expression of POEM mRNA
(Fig. 1). Subsequently, regulation of POEM gene expression
by TGF-b was further examined.
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a time- and dose-dependent manner
WhenMC3T3-E1 cells were treated with diﬀerent concentra-
tions of TGF-b for 48 h, a signiﬁcant decrease of POEM
mRNAwas observed when TGF-b concentrations were greater
than 100 pg/ml as compared with that in the absence of TGF-b.
(Fig. 2A). A time-dependent eﬀect of TGF-b on the inhibition
of POEM mRNA was further examined using a ﬁxed concen-
tration of 1 ng/ml TGF-b. Levels of POEM mRNA continued
to increase up to 24 h without any treatment. Inhibition of
POEM expression became noticeable 3 h after the initiation
of TGF-b treatment (Fig. 2B). These ﬁndings showed that
TGF-b suppressed expression of POEM mRNA in a dose-
and time-dependent manner in MC3T3-E1 cells. Furthermore,
we investigated the eﬀects of TGF-b on the expressions of
osoteoblast diﬀerentiation markers such as ALP, osteocalcin
and bone sialo protein (BSP) mRNAs. Each of these genes
was downregulated by TGF-b in a manner consistent with that
of POEM mRNA (Fig. 2C).
3.3. BMP-2 did not aﬀect POEM gene expression in osteoblasts
BMPs, members of the TGF-b superfamily, are thought to
play a major role in the control of bone formation [18]. BMPs
and TGF-b exhibit opposite eﬀects on the regulation of gene
expression in many systems. For example, BMPs stimulate
the expressions of ALP, osteocalcin, BSP, and type I collagen,
[19–21] whereas, TGF-b can markedly suppress those genes
(Fig. 2C) [22–24]. To examine whether POEM gene expression
is regulated by BMP-2, a time-dependent eﬀect of BMP-2 on
the expression of POEM mRNA was examined using a ﬁxed
concentration of 100 ng/ml BMP-2. BMP-2 did not aﬀect the
expression of POEMmRNA up to 24 h (Fig. 3A and B). These
ﬁndings suggest that the mechanism of POEM gene expressionPOEM
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Fig. 3. Eﬀect of BMP-2 on POEM mRNA expression. (A) Time course ana
were treated with 1 ng/ml TGF-b for 3, 6, 12, 24, or 48 h. Total cellular RNAs
Northern blot analysis. (B) Signals for POEM and GAPDH were quantitated
normalizing to those of GAPDH was plotted.is diﬀerent from that of osteoblast marker genes such as ALP,
osteocalcin and BSP for BMP signaling.
3.4. Downregulation of POEM mRNA by TGF-b is through
TGF-b receptor I
TGF-b binds to cell surface receptor complexes, type I
(TGF-b RI) and type II (TGF-b RII) receptors, leading to
the activation of intracellular signaling molecules, such as
SMADs, MAPKs and other molecules [15]. To study the
mechanism of TGF-b-induced downregulation of POEM gene
expression, the presence of TGF-b RI and TGF-b RII was ﬁrst
examined using RT-PCR analysis. The ﬁndings clearly demon-
strated that both type I and type II TGF-b receptors were pres-
ent in MC3T3-E1 cells similar to those in primary ostoblasts
(Fig. 4A). When MC3T3-E1 cells were treated with TGF-b
RI kinase inhibitor II, a selective inhibitor of its serine/threo-
nine kinase activity [25], before the addition of TGF-b, the
downregulation of POEM gene expression by TGF-b was
inhibited in an inhibitor concentration-dependent manner
(Fig. 4B). Interestingly, only TGF-b receptor kinase inhibitor
II treatment of MC3T3-E1 cells induced POEM gene expres-
sion in a dose-dependent manner (Fig. 4B). Inhibition of
POEM gene expression may be partly explained by low levels
of endogenous TGF-b receptor kinase activation. These ﬁnd-
ings suggest that the downregulation of POEM mRNA by
TGF-b occurs through TGF-b receptor I activation.
3.5. The ERK1/2 and JNK pathways are responsible for the
downregulation of POEM mRNA by TGF-b
TGF-b stimulates MAPKs, such as ERK1/2, p38 MAPK
and JNK, in a variety of cell lines including MC3T3-E1 cells
[26,27] (also shown in Fig. 5A). To determine whether MAPK
pathways are involved in the downregulation of POEM gene6 12 24
ture Period (h)
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lysis of TGF-b eﬀects on POEM mRNA expression. MC3T3-E1 cells
were extracted and mRNA for POEM and GAPDH were examined by
using Image J software. The relative fold in POEM mRNA levels after
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Fig. 4. Inhibition of POEM mRNA expression by TGF-b requires activation of TGF-b receptor I kinase. (A) RT-PCR analysis for the presence of
TGF-b receptors in primary osteoblasts and MC3T3-E1 cells. The size of PCR products were 409 bp for TGF-b receptor I, 418 bp for TGF-b
receptor II and 982 bp for GAPDH. (B) A selective inhibitor of TGF-b receptor I kinase inhibited downregulation of POEM mRNA expression by
TGF-b. MC3T3-E1 cells were pretreated with 0.1, 1 or 10 mM TGF-b receptor I kinase inhibitor II for 1 h followed by treatment with 1 ng/ml TGF-
b in the presence of the inhibitor for 12 h. After extracting total cellular RNA samples from duplicate cultures for each condition, mRNAs for POEM
and GAPDH were examined by Northern blot analysis.
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10 lM of PD098059 (MAPK-ERK kinase (MEK) inhibitor),
SB203580 (p38 MAPK inhibitor), or SP600125 (JNK inhibi-
tor) for 1 h followed by treatment with 0.1 ng/ml TGF-b in
the presence of the inhibitors for 48 h. Treatment of
PD98059 and SP600125, not but that of SB203580, inhibited
downregulation of POEM gene expression by TGF-b
(Fig. 5B). It should be noted that enhancement of basal POEM
expression by PD098059 and SP600125 could recover suppres-
sion of basal POEM expression independently of TGF-b.
These ﬁndings suggest that ERKs and SAPK/JNK activation
by TGF-b downregulate POEM gene expression.4. Discussion
The present study demonstrates that POEM can be regu-
lated by TGF-b through TGF-b receptor I activation. TGF-
b activates both ERK1/2 and JNK pathways, leading to the
downregulation of POEM gene expression in MC3T3-E1 cells.
TGF-b stimulates the production of some extra-cellular ma-
trix proteins, such as collagens, ﬁbronectin, and proteoglycans
in a various of cell types [28]. Further, TGF-b also stimulates
the production of integrins which are the principal receptors
for binding found on most extracellular matrix proteins,
including collagens, ﬁbronectin, and laminins [29]. Thus,
TGF-b generally promotes the adhesion of cells to the extra-
cellular matrix, which results in the promotion of a ﬁbrotic re-
sponse and vascularization [30,31]. Interestingly, POEM
seemed to enhance the formation of new capillaries from
pre-existing vessels in a chicken chorioallantoic membrane
(CAM) assay (N. Morimura et al., unpublished data). In con-trast, in the present study, POEM, a cell adhesion molecule,
was downregulated in osteoblasts following TGF-b treatment.
Therefore, the eﬀects of TGF-b on POEM gene expression are
not the same as those on other cell adhesion molecules regu-
lated by TGF-b. However, the present ﬁndings did not indicate
the precise physiological and functional roles of POEM gene
regulation by TGF-b. Nevertheless, examination of whether
the regulation of POEM expression by TGF-b is involved di-
rectly or indirectly in the proliferation and diﬀerentiation of
osteoblasts is important and should be further examined.
Sowa et al. showed that inactivation of ERK1/2 and JNK
with their speciﬁc inhibitors antagonized the inhibitory eﬀects
of TGF-b on SMAD3-induced ALP activity and mineraliza-
tion in MC3T3-E1 cells [27]. Our ﬁndings were similar to
theirs, and suggested that activation of ERK1/2 and JNK con-
tributes to the inhibitory regulation of POEM. The AP-1 fam-
ily protein c-Jun, which is a substrate for JNK, directly
suppressed transcription factors/DNA interaction [32]. Fur-
ther, treatment with epidermal growth factor (EGF) sup-
pressed POEM gene expression, which may occur through
activation of the ERK1/2-MAPK pathway (A. Miyazono
et al., unpublished data).
The present ﬁndings did not clarify the exact molecular
mechanism involved in POEM gene regulation by SMAD acti-
vation, because TGF-b receptor I kinase inhibitor used in our
experiments is not a speciﬁc SMAD pathway antagonist,
though it completely abrogated SMAD2 phosphorylation by
TGF-b stimulation (data not shown). The ALK-5 inhibitors
were shown to have limited eﬀects on activation of p38
MAPK, JNK1/3 kinase and other kinases [25], and had no ef-
fect on ERK1/2 and JNK phosphorylation by TGF-b (data
not shown). However, the inhibitors of the ERK/JNK path-
Culture Period (min)
0 10 20 30
pJNK
JNK
pERK1/2
ERK1/2
pp38 MAPK
p38 MAPK
POEM
GAPDH
TGF-β  (0.1 ng/ml)
PD98059 (10 μM)
SB203580 (10 μM)
SP600125 (10 μM)
A
B
Fig. 5. Inhibition of POEM mRNA expression by TGF-b requires
activation of the ERK1/2 and JNK. (A) MAPKs (ERK1/2, p38
MAPK, and JNK) activation in MC3T3-E1 cells by TGF-b stimula-
tion. MC3T3-E1 cells were treated with 0.1 ng/ml TGF-b for 10, 20, or
30 min. Activation of ERK1/2, p38 MAPK and JNK was measured by
the presence of phosphorylated ERK1/2 (Thr202/Tyr204), p38 MAPK
(Thr180/Tyr182), and JNK (Thr183/Tyr185) bands. (B) Involvement
of MAPK pathways in POEM mRNA expression following TGF-b
treatment. MC3T3-E1 cells were pretreated with 10 lM PD98059,
10 lM SB203580, or 10 lM SP600125 for 1 h followed by treatment
with 0.1 ng/ml TGF-b in the presence of inhibitors for 48 h. Total
cellular RNAs were extracted and mRNAs for POEM and GAPDH
were examined by Northern blot analysis.
TGF-β
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JNK
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SP600125 PD98059
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Fig. 6. Model of TGF-b induced inhibition of POEM gene expression.
TGF-b activates the ERK1/2 and JNK signaling pathways leading to
the inhibition of POEM gene expression.
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mRNA expression, as clearly shown in Fig. 5B. Thus, we con-
cluded that POEM gene expression by TGF-b is dominantly
regulated through the ERK/JNK pathways, though we cannot
exclude the possibility that it may also be regulated by the
SMAD signaling pathway (Fig. 6).
TGF-b stimulates pre-osteoblast proliferation while inhibit-
ing full diﬀerentiation and accordingly, inhibits the expression
of ALP, BSP, osteocalcin, and other markers of osteoblast
function [22–24] (also shown in Fig. 2C). A key event in this
inhibition is repression of the Runx2 function by TGF-b,
thereby downregulating the expression of Runx2 target genes,
such as ALP, osteocalcin, and Runx2 [22,24,33]. Although
BMPs enhance the expression of all these genes as well as
osteoblast diﬀerentiation through Runx2 [34], POEM mRNA
expression was not increased by BMP-2 stimulation (Fig. 3).
Therefore, downregulation of POEM expression by TGF-b
may not be related to osteoblast diﬀerentiation induced by
Runx2. Additional studies are needed to ascertain whether
the regulation of POEM expression by TGF-b is involved in
bone metabolism.
In summary, POEM gene expression is regulated by TGF-b
through its own receptor, TGF-b RI, and the MAPK path-
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